- +86 0371-86658258
- info@coreychem.com
English
| Product Name | AZD-9291 |
| Synonyms | N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide;AZD929/Osimertinib;OsimertinibIntermediate4;Osimertinib,98%,apotentandselectivemutatedformsEGFRinhibitor;PharmaChemicalbookceuticalChemicalAnticancerDrugAzd-9291forforLungCancer1421373-65-0;Mereletinib;N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide;Mereletinibmesylate(AZD9291) |
| CAS NO | 1421373-65-0 |
| Purity | 99% |
| MF | C28H33N7O2 |
| MW | 499.61 |
| Contact | selina@coreychem.com |
AZD-9291 (CAS: 1421373-65-0), also known as Osimertinib, is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by AstraZeneca.
Main Applications:
Designed to target EGFR T790M mutations, which are a common mechanism of resistance in non-small cell lung cancer (NSCLC) patients previously treated with first-generation EGFR TKIs (e.g., gefitinib, erlotinib).
It selectively inhibits mutant forms of EGFR while sparing wild-type EGFR, reducing off-target side effects.
Widely used in advanced NSCLC therapy as a first-line or second-line treatment option.
Osimertinib is FDA- and EMA-approved and is considered a standard of care in the treatment of EGFR mutation-positive advanced or metastatic NSCLC.
25KG/50KG/200KG per barrel;
Or package according to customer needs
